MCM
AMED

Manchester Capital Management’s Amedisys AMED Stock Holding History

Manchester Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,140
Closed -$2.85M – 1005
2021
Q3 		$2.85M Buy
+19,140
New +$3.98M 0.39% 36

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Manchester Capital Management's AMED Position: Q4 2021 in Review

Manchester Capital Management sold out of Amedisys (AMED) in Q4 2021, closing a stake of 19,140 shares — an estimated $2.85M sold.

Manchester Capital Management first reported a position in AMED in Q3 2021 and held it in 1 quarter. The position peaked at $2.85M in Q3 2021. 324 funds tracked by Wall St. Rank hold AMED as of Q4 2021.

  • Manchester Capital Management reported no remaining Amedisys position as of Q4 2021 after selling out during the quarter.
  • Manchester Capital Management sold 19,140 Amedisys shares in Q4 2021, an estimated $2.85M.
  • Manchester Capital Management first reported a position in Amedisys in Q3 2021 and held it in 1 quarter.
  • Manchester Capital Management's Amedisys position peaked at $2.85M in Q3 2021.
  • 324 funds tracked by Wall St. Rank held Amedisys as of Q4 2021.

Based on Manchester Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.